; sense of Congress (a) Findings Congress finds the following: (1) The Centers for Disease Control and Prevention estimates that approximately 1,200,000 individuals in the United States are living with HIV. (2) In 2021, there were 36,136 new diagnoses of HIV in the United States. (3) HIV disproportionately impacts gay and bisexual men, transgender women, and, in particular, people of color. In 2021, approximately 71 percent of new HIV diagnoses were estimated to be among gay and bisexual men, 40 percent of new HIV diagnoses were among Black people, and 29 percent of new HIV diagnoses were among Latinx people. Recent studies suggest that transgender women are up to 49 times more likely to be diagnosed with HIV than the general population. Members of communities at the intersections of these groups are most heavily impacted. (4) Pre-exposure prophylaxis (referred to in this section as PrEP ) is a daily antiretroviral medication that helps prevent individuals from acquiring HIV. Daily PrEP use reduces the risk of getting HIV from sex by more than 99 percent. It reduces the risk of getting HIV from injection drug use by at least 74 percent. (5) Many individuals at risk of exposure to HIV do not use PrEP. Of the approximately 1,200,000 individuals in the United States who could benefit from PrEP, only 31 percent, or 382,364 individuals, filled prescriptions for the drug in 2022. (6) PrEP usage is inconsistent across racial and gender lines. In 2022, only 11 percent of Black/African American and 21 percent of Hispanic/Latinx individuals who were eligible for PrEP were prescribed it, compared to 82 percent of eligible White individuals. PrEP usage is low among women, in particular among heterosexual women of color, slightly less than 12 percent of women eligible for PrEP received a prescription in 2022. (7) PrEP use helps strengthen families by allowing couples with partners of different HIV statuses to prevent the transmission of HIV. (8) There are currently 2 brand name drugs and 1 generic drug approved by the Food